eClinical Technology and Industy News

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells

Misetionamide reduces energy metabolism by inhibiting aerobic glycolysis

Excerpt from the Press Release:

BERWYN, PA, Feb. 01, 2024 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Anti-Cancer Drugs in an article titled, “Antineoplastic Activity of GP-2250 In Vitro and in Mouse Xenograft Models.”1 The publication by Sofia et al. (2024) provided early research evidence that misetionamide exhibits a dose-dependent antineoplastic effect on both established cancer cell lines and xenograft models from patient tissues.2 Antineoplastic activity was tested in over 300 cancer cell lines using the OncoPanel® cytotoxicity assay and was further tested in eight human cancer xenograft models.

Results included a reduction of 30-40% of tumor volume in xenograft mouse models treated with misetionamide and demonstrated a reduction in the progression of tumor cell volume in multiple cancer cell lines including pancreatic and ovarian cancer suggesting a strong antineoplastic effect. Most notably in the ovarian tumor xenograft model, misetionamide produced a regression in the original tumor volume. Concentrations for IC50 and EC50 were determined as was the concentration at which a 10-fold increase in apoptosis was induced. All these concentrations have subsequently been shown to be clinically achievable in an on-going Phase 1 clinical trial. In addition, misetionamide was also shown to induce a cancer cell cycle block that would inhibit tumor cells from replicating and thus inhibiting tumor growth. The results of these studies also reinforce the results of other studies demonstrating strong synergism with other anticancer agents, including gemcitabine, bevacizumab, and PARP inhibitors. To that end, the results support the development of misetionamide as a promising new therapeutic agent with a unique mechanism of action for human cancers.

“While this paper details the early screening work in 300 human cancer lines using in vitro studies as well as 8 in vivo studies to determine if misetionamide showed any antineoplastic activity, and, if so, in which cancer cells, we were pleased that the results showed both the very broad activity in many cancer cell lines and that normal cells were not detrimentally affected, said R. Duane Sofia, PhD, Head Nonclinical Research, Panavance Therapeutics.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?